SHANGHAI, July 13, 2018 /PRNewswire/ — OrigiMed announces an agreement with Illumina in Shanghai, China. It will develop and promote its advanced molecular clinical tumor applications to the public based on the Next Generation Sequencing (NGS) technology of Illumina. This marks further cooperation between Illumina and Chinese enterprises. It also signals that genomics technology will play an increasingly important future role in the fast-developing market of precise diagnosis of cancer.
Recently, NGS has emerged as the key technology in precision medicine. The Chinese market has huge potential to apply NGS technology because of its large cancer patient population – more than 4 million new cancer patients identified in China each year. The cooperation between OrigiMed and Illumina means that the world’s leading NGS technology will cover more widely the Chinese market. As an important part of the cooperation, Illumina will provide NGS instruments and related reagents, and OrigiMed will focus on the clinical applications in tumor molecular diagnosis and provide self-developed and a patterned bioinformatics solution to the medical institutions. In the future, OrigiMed plans to develop a total sequencing solution for clinical applications.
OrigiMed is a medical science and technology transforming company which focuses on developing new technologies and clinical applications for all types of cancer patients. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation, we identify cancer specific molecular markers and genomic features to guide targeted or immuno-therapy, ultimately aim to fortify the evolution of cancer precision medicine in China.
View original content with multimedia:http://www.prnewswire.com/news-releases/origimed-collaborates-with-illumina-to-further-develop-and-promote-its-advanced-clinical-molecular-tumor-applications-300680548.html